1
|
Rebibo L, Tam C, Sun Y, Shoshani E, Badihi A, Nassar T, Benita S. Topical tacrolimus nanocapsules eye drops for therapeutic effect enhancement in both anterior and posterior ocular inflammation models. J Control Release 2021; 333:283-297. [PMID: 33798665 DOI: 10.1016/j.jconrel.2021.03.035] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2021] [Accepted: 03/25/2021] [Indexed: 02/06/2023]
Abstract
Tacrolimus has shown efficacy in eye inflammatory diseases. However, due to the drug lability, its formulation into a stable ophthalmic product remains a challenge. Tacrolimus-loaded nanocapsules (NCs) were designed for ocular instillation. Further, the stability and effects of the formulation were analyzed under different experimental conditions. Physicochemical characterization of the NCs revealed suitable homogeneous size and high encapsulation efficiency. Moreover, the lyophilized formulation was stable at ICH long term and accelerated storage conditions, for at least 18 and 3 months, respectively. The tacrolimus NCs did not elicit any eye irritation in rabbits after single- and multiple-dose applications. Additionally, ex vivo penetration assays on isolated porcine cornea and pharmacokinetics analyses in various rabbit eye compartments demonstrated the superiority of the NCs in retention and permeation into the anterior chamber of the eye compared to the free drug dissolved in oil. Moreover, multiple dose ocular instillation of the NCs in rats allowed high tacrolimus levels in the eye with very low plasma concentrations. Finally, the developed delivery system achieved a significant decrease in four typical inflammatory markers in a murine model of keratitis, an anterior chamber inflammation. Furthermore, these NCs, applied as eye drops, displayed clinical and histological efficacy in the mainly posterior chamber inflammation model of murine, experimental auto-immune uveitis.
Collapse
Affiliation(s)
- Leslie Rebibo
- Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
| | - Connie Tam
- Department of Ophthalmic Research, Cole Eye Institute and Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
| | - Yan Sun
- Department of Ophthalmic Research, Cole Eye Institute and Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA
| | | | | | - Taher Nassar
- Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
| | - Simon Benita
- Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel; BioNanoSim Ltd., Jerusalem, Israel.
| |
Collapse
|
3
|
Li J, Qiu C, Zhang Z, Yuan W, Ge Z, Tan B, Yang P, Liu J, Zhu X, Qiu C, Lai D, Guo L, Yu L. Subretinal Transplantation of Human Amniotic Epithelial Cells in the Treatment of Autoimmune Uveitis in Rats. Cell Transplant 2018; 27:1504-1514. [PMID: 30168350 PMCID: PMC6180726 DOI: 10.1177/0963689718796196] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023] Open
Abstract
As a featured ocular inflammatory disease, autoimmune uveitis is the major cause of blindness in the clinic. Although current immunosuppressive regimens can alleviate the progression of autoimmune uveitis, they have serious side effects. Therefore, an alternative therapeutic strategy is urgently required. The present study investigated the therapeutic efficacy of human amniotic epithelial cells (hAECs) on autoimmune uveitis in a rat model. Herein, experimental autoimmune uveitis (EAU) was induced in rats via a subcutaneous injection of interphotoreceptor retinoid-binding protein. EAU rats were treated with hAECs or the vehicle solution via a subretinal injection on day 0 and day 6 after immunization, and rats were sacrificed on day 12 and day 18 for further analysis. The pathological development of EAU was evaluated by slit lamp microscopy. Immune cell infiltration and retinal structure damage were examined by histological examination of hematoxylin and eosin (H&E) and immunofluorescence staining. T-cell subsets were detected by flow cytometry, and the levels of inflammatory cytokines were quantified by enzyme-linked immunosorbent assay (ELISA). hAEC treatment ameliorated the pathological progression of EAU and preserved the retinal structure organization and thickness, especially in the preventive group that received a subretinal injection on day 0. Moreover, hAECs inhibited the retinal infiltration of macrophages and T-cells. Mechanistically, hAECs modulated the balance of T-cell subsets by downregulating T helper (Th)17 cells and upregulating T regulatory (Treg) cells, as confirmed by decreased interleukin (IL)-17 and increased IL-10 levels in the spleens and lymph nodes of EAU rats. Furthermore, hAECs improved the local cytokine environment in EAU rats by suppressing the monocyte chemoattractant protein (MCP)-1, IL-17 and interferon (IFN)-γ levels and enhancing the IL-10 in the aqueous humor. Therefore, subretinal transplantation of hAECs in EAU rats ameliorated ocular inflammation, preserved the retinal structure and coordinated the immune balance. The current study provides a novel therapeutic strategy for autoimmune uveitis and related ocular inflammatory diseases in the clinic.
Collapse
Affiliation(s)
- Jinying Li
- 1 Institute of Genetics and Regenerative Biology, College of Life Sciences, Hangzhou, Zhejiang, China.,2 College of Life Sciences-iCell Biotechnology Regenerative Biomedicine Laboratory, Hangzhou, Zhejiang, China.,3 Center for Stem Cell and Regenerative Medicine, Hangzhou, Zhejiang, China
| | - Chen Qiu
- 1 Institute of Genetics and Regenerative Biology, College of Life Sciences, Hangzhou, Zhejiang, China.,2 College of Life Sciences-iCell Biotechnology Regenerative Biomedicine Laboratory, Hangzhou, Zhejiang, China.,3 Center for Stem Cell and Regenerative Medicine, Hangzhou, Zhejiang, China
| | - Zheng Zhang
- 4 The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
| | - Weixin Yuan
- 1 Institute of Genetics and Regenerative Biology, College of Life Sciences, Hangzhou, Zhejiang, China.,2 College of Life Sciences-iCell Biotechnology Regenerative Biomedicine Laboratory, Hangzhou, Zhejiang, China.,3 Center for Stem Cell and Regenerative Medicine, Hangzhou, Zhejiang, China
| | - Zhen Ge
- 5 Institute of Materia Medica, Zhejiang Academy of Medical Sciences, Hangzhou, Zhejiang, China
| | - Bing Tan
- 1 Institute of Genetics and Regenerative Biology, College of Life Sciences, Hangzhou, Zhejiang, China.,2 College of Life Sciences-iCell Biotechnology Regenerative Biomedicine Laboratory, Hangzhou, Zhejiang, China.,3 Center for Stem Cell and Regenerative Medicine, Hangzhou, Zhejiang, China
| | - Pengjie Yang
- 1 Institute of Genetics and Regenerative Biology, College of Life Sciences, Hangzhou, Zhejiang, China.,2 College of Life Sciences-iCell Biotechnology Regenerative Biomedicine Laboratory, Hangzhou, Zhejiang, China.,3 Center for Stem Cell and Regenerative Medicine, Hangzhou, Zhejiang, China
| | - Jia Liu
- 1 Institute of Genetics and Regenerative Biology, College of Life Sciences, Hangzhou, Zhejiang, China.,2 College of Life Sciences-iCell Biotechnology Regenerative Biomedicine Laboratory, Hangzhou, Zhejiang, China.,3 Center for Stem Cell and Regenerative Medicine, Hangzhou, Zhejiang, China
| | - Xiaolong Zhu
- 1 Institute of Genetics and Regenerative Biology, College of Life Sciences, Hangzhou, Zhejiang, China.,2 College of Life Sciences-iCell Biotechnology Regenerative Biomedicine Laboratory, Hangzhou, Zhejiang, China.,3 Center for Stem Cell and Regenerative Medicine, Hangzhou, Zhejiang, China
| | - Cong Qiu
- 1 Institute of Genetics and Regenerative Biology, College of Life Sciences, Hangzhou, Zhejiang, China.,2 College of Life Sciences-iCell Biotechnology Regenerative Biomedicine Laboratory, Hangzhou, Zhejiang, China.,3 Center for Stem Cell and Regenerative Medicine, Hangzhou, Zhejiang, China
| | - Dongmei Lai
- 6 International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
| | - Lihe Guo
- 7 Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China.,8 Shanghai iCELL Biotechnology Co Ltd, Shanghai, China
| | - Luyang Yu
- 1 Institute of Genetics and Regenerative Biology, College of Life Sciences, Hangzhou, Zhejiang, China.,2 College of Life Sciences-iCell Biotechnology Regenerative Biomedicine Laboratory, Hangzhou, Zhejiang, China.,3 Center for Stem Cell and Regenerative Medicine, Hangzhou, Zhejiang, China
| |
Collapse
|
4
|
Clark SJ, Bishop PN. The eye as a complement dysregulation hotspot. Semin Immunopathol 2017; 40:65-74. [PMID: 28948331 PMCID: PMC5794836 DOI: 10.1007/s00281-017-0649-6] [Citation(s) in RCA: 79] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2017] [Accepted: 08/30/2017] [Indexed: 01/23/2023]
Abstract
Complement turnover is tightly regulated throughout the human body in order to prevent over-activation and subsequent damage from inflammation. In the eye, low-level complement activation is maintained to provide immune tolerance in this immune privileged organ. Conversely, the complement system is suppressed in the cornea to protect it from continuous immunological insult. Over-activation of the complement cascade has been implicated in the disease progression of glaucoma and diabetic retinopathy and is now known to be a central driver in the pathogenesis of age-related macular degeneration (AMD). Indeed, it is with AMD where the most recent and exciting work has been carried out with complement-based therapies entering into clinical trials. However, the success of these trials will depend upon delivering the therapeutics to the correct anatomical sites within the eye, so a full understanding of how complement regulation is compartmentalized in the eye is required, a topic that will be highlighted in this review.
Collapse
Affiliation(s)
- Simon J Clark
- Division of Evolution and Genomic Medicine, School of Biological Sciences, Faculty of Biology Medicine and Health, University of Manchester, Oxford Road, Manchester, M13 9PT, UK.
| | - Paul N Bishop
- Division of Evolution and Genomic Medicine, School of Biological Sciences, Faculty of Biology Medicine and Health, University of Manchester, Oxford Road, Manchester, M13 9PT, UK.,Manchester Royal Eye Hospital, Manchester Academic Health Science Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK
| |
Collapse
|
7
|
Agarwal RK, Horai R, Viley AM, Silver PB, Grajewski RS, Su SB, Yazdani AT, Zhu W, Kronenberg M, Murray PJ, Rutschman RL, Chan CC, Caspi RR. Abrogation of anti-retinal autoimmunity in IL-10 transgenic mice due to reduced T cell priming and inhibition of disease effector mechanisms. JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 2008; 180:5423-9. [PMID: 18390724 PMCID: PMC2442578 DOI: 10.4049/jimmunol.180.8.5423] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Experimental autoimmune uveitis (EAU) induced by immunization of animals with retinal Ags is a model for human uveitis. The immunosuppressive cytokine IL-10 regulates EAU susceptibility and may be a factor in genetic resistance to EAU. To further elucidate the regulatory role of endogenous IL-10 in the mouse model of EAU, we examined transgenic (Tg) mice expressing IL-10 either in activated T cells (inducible) or in macrophages (constitutive). These IL-10-Tg mice and non-Tg wild-type controls were immunized with a uveitogenic regimen of the retinal Ag interphotoreceptor retinoid-binding protein. Constitutive expression of IL-10 in macrophages abrogated disease and reduced Ag-specific immunological responses. These mice had detectable levels of IL-10 in sera and in ocular extracts. In contrast, expression of IL-10 in activated T cells only partially protected from EAU and marginally reduced Ag-specific responses. All IL-10-Tg lines showed suppression of Ag-specific effector cytokines. APC from Tg mice constitutively expressing IL-10 in macrophages exhibited decreased ability to prime naive T cells, however, Ag presentation to already primed T cells was not compromised. Importantly, IL-10-Tg mice that received interphotoreceptor retinoid-binding protein-specific uveitogenic T cells from wild-type donors were protected from EAU. We suggest that constitutively produced endogenous IL-10 ameliorates the development of EAU by suppressing de novo priming of Ag-specific T cells and inhibiting the recruitment and/or function of inflammatory leukocytes, rather than by inhibiting local Ag presentation within the eye.
Collapse
Affiliation(s)
- Rajeev K. Agarwal
- The Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD 20892
| | - Reiko Horai
- The Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD 20892
| | - Angelia M. Viley
- The Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD 20892
| | - Phyllis B. Silver
- The Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD 20892
| | - Rafael S. Grajewski
- The Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD 20892
| | - Shao Bo Su
- The Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD 20892
| | - Arrash T. Yazdani
- The Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD 20892
| | - Wei Zhu
- The Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD 20892
| | | | - Peter J. Murray
- Department of Infectious Diseases, St. Jude Children's Hospital, Memphis, TN 38105
| | - Robert L. Rutschman
- Department of Infectious Diseases, St. Jude Children's Hospital, Memphis, TN 38105
| | - Chi-Chao Chan
- The Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD 20892
| | - Rachel R. Caspi
- The Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD 20892
| |
Collapse
|